The ubiquitin-like molecule interferon-stimulated gene 15 is overexpressed in human prostate cancer.

To identify molecules to serve as diagnostic markers for high-grade prostate cancer (PC) and targets for novel therapeutic drugs, we investigated the gene expression profiles of high-grade PCs using a cDNA microarray combined with laser microbeam microdissection. We subsequently confirmed that the ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) was expressed exclusively in high-grade PCs with high Gleason scores. Semi-quantitative reverse transcription PCR and immunohistochemical analysis confirmed the overexpression of ISG15, a 165 amino acid interferon-inducible ubiquitin-like protein, specifically in high-grade PCs with high Gleason scores 8-9, while it was not expressed in the normal prostate. Immunohistochemical analysis using anti-ISG15 polyclonal antibody confirmed an elevated expression of ISG15 protein in high-grade PCs as well as low-grade PCs compared with that in normal prostate (NP) epithelium. Knockdown of ISG15 expression by short interfering RNA (siRNA) in a PC cell line resulted in marked attenuation of PC cell survival; concordantly, ISG15 overexpression in a PC cell line promoted PC cell growth, indicating its oncogenic property. These findings suggest that ISG15 is involved in cell growth and survival of PCs and that it could be a potential molecular target for new therapeutics and a diagnostic biomarker for human PCs.

[1]  M. Hochstrasser,et al.  Evolution and function of ubiquitin-like protein-conjugation systems , 2000, Nature Cell Biology.

[2]  B. Korant,et al.  Interferon-induced proteins. Purification and characterization of a 15,000-dalton protein from human and bovine cells induced by interferon. , 1984, The Journal of biological chemistry.

[3]  G. Stark How cells respond to interferons revisited: from early history to current complexity. , 2007, Cytokine & growth factor reviews.

[4]  H. Scher,et al.  Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. Feldman,et al.  The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.

[6]  S. Devesa,et al.  Trends and patterns of prostate cancer: what do they suggest? , 2001, Epidemiologic reviews.

[7]  A. Chokkalingam,et al.  Prostate cancer epidemiology. , 2006, Frontiers in bioscience : a journal and virtual library.

[8]  E. Borden,et al.  Proteomic identification of proteins conjugated to ISG15 in mouse and human cells. , 2005, Biochemical and biophysical research communications.

[9]  A. Haas,et al.  Interferon induces a 15-kilodalton protein exhibiting marked homology to ubiquitin. , 1987, The Journal of biological chemistry.

[10]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[11]  Steven Gygi,et al.  Human ISG15 conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[12]  P. Lengyel,et al.  Accumulation of an mRNA and protein in interferon-treated Ehrlich ascites tumour cells , 1979, Nature.

[13]  K. Loeb,et al.  The interferon-inducible 15-kDa ubiquitin homolog conjugates to intracellular proteins. , 1992, The Journal of biological chemistry.

[14]  B. Williams,et al.  Functional classification of interferon‐stimulated genes identified using microarrays , 2001, Journal of leukocyte biology.

[15]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[16]  A W Partin,et al.  Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. , 2001, The Journal of urology.

[17]  E. Borden,et al.  High-throughput Immunoblotting , 2003, The Journal of Biological Chemistry.